Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

Czech Republic-based Zentiva Pharma, a generics and over-the-counter medicines company that is wholly-owned by private equity ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

A new study presented at the American Academy of Orthopedic Surgeons meeting reveals the need to stop taking GLP-1 agonists ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of ...

The global anorexiant market is set for significant expansion, with a projected compound annual growth rate (CAGR) of 5.1% over the forecast period, according to a recent study by Future Market ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the first generics company to receive approval for Liraglutide in a major ...

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...